# A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

> **NCT05996471** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 185 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VH3810109
- **DRUG:** Cabotegravir
- **DRUG:** Standard of care (SOC)
- **BIOLOGICAL:** rHuPH20

## Key facts

- **NCT ID:** NCT05996471
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-17
- **Primary completion:** 2026-05-22
- **Final completion:** 2028-11-09
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05996471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05996471, "A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05996471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*